Saturday 17 October 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.21
0.32
−2.37%
Follow IART
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
46.55 | 57.16 | 62.64 | 100.48 | 41.20 | 33.83 | 25.79 | 52.11 | 0.00 | 0.00 |
Piotroski F-Score |
8 | 3 | 5 | 6 | 6 | 7 | 8 | 4 | 5 | 5 |
P/S ratio |
3.19 | 3.03 | 2.54 | 3.29 | 4.01 | 3.68 | 2.97 | 2.25 | 1.08 | 0.58 |
Altman Z-Score |
3.15 | 1.70 | 2.24 | 2.50 | 2.57 | 2.72 | 2.52 | 2.05 | 1.22 | 0.62 |
P/FCF ratio |
45.65 | 50.53 | 30.54 | 30.82 | 32.60 | 21.46 | 19.82 | 47.39 | 69.96 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.08 | 1.80 | 2.52 | 2.42 | 3.04 | 3.21 | 3.48 | 3.08 | 1.72 | 1.17 |
Beneish M-Score |
(2.50) | (2.14) | (2.52) | (2.70) | (2.80) | (2.56) | (2.42) | (2.56) | (2.61) | (3.25) |
P/Operating CF |
485.24 | 312.08 | 87.54 | 55.96 | 68.47 | 81.90 | 54.18 | 58.96 | 34.42 | 80.59 |
P/B ratio |
3.77 | 3.75 | 2.72 | 3.52 | 3.63 | 3.37 | 2.56 | 2.18 | 1.13 | 0.91 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.76 | 4.40 | 3.35 | 4.05 | 4.77 | 4.36 | 3.61 | 3.06 | 2.01 | 1.53 |
EV/EBITDA |
19.60 | 38.27 | 21.64 | 29.49 | 22.20 | 20.74 | 15.45 | 19.55 | 18.54 | 0.00 |
EV/Operating CF |
32.08 | 45.60 | 24.71 | 26.58 | 32.11 | 21.51 | 21.27 | 33.69 | 25.06 | 49.74 |
EV/FCF |
53.81 | 73.22 | 40.32 | 37.99 | 38.83 | 25.42 | 24.11 | 64.52 | 129.88 | (80.70) |
Quick Ratio |
2.02 | 1.22 | 1.54 | 1.43 | 1.73 | 2.19 | 2.24 | 1.85 | 0.59 | 1.19 |
Current Ratio |
4.01 | 2.36 | 2.95 | 2.59 | 3.09 | 3.39 | 3.62 | 3.45 | 1.17 | 2.54 |
Net Debt/EBITDA |
2.95 | 12.21 | 5.33 | 5.57 | 3.56 | 3.23 | 2.75 | 4.88 | 8.55 | (4.62) |
Debt/Assets |
36.78% | 57.33% | 43.59% | 41.17% | 42.07% | 41.28% | 37.49% | 39.27% | 43.82% | 50.45% |
Debt/Equity |
0.79 | 1.91 | 0.98 | 0.96 | 1.00 | 0.93 | 0.81 | 0.94 | 1.14 | 1.74 |
Asset Turnover |
0.55 | 0.47 | 0.47 | 0.47 | 0.40 | 0.42 | 0.41 | 0.40 | 0.41 | 0.43 |
Operating CF/Net income |
1.56 | 1.77 | 3.28 | 4.61 | 1.52 | 1.85 | 1.46 | 2.07 | (18.63) | (0.10) |
Capex/Depreciation |
(0.63) | (0.47) | (0.66) | (0.61) | (0.25) | (0.38) | (0.25) | (0.52) | (0.78) | (0.61) |
Interest Coverage |
4.47 | 1.28 | 1.72 | 1.74 | 2.11 | 3.91 | 4.82 | 2.17 | 0.40 | (5.72) |
| 9.37% | 7.19% | 5.20% | 3.60% | 9.13% | 10.57% | 10.35% | 3.99% | (0.44%) | (39.90%) | |
| 4.16% | 2.58% | 1.92% | 1.57% | 3.87% | 4.57% | 4.71% | 1.77% | (0.18%) | (13.52%) | |
ROIC |
5.14% | 1.07% | 2.68% | 2.27% | 3.69% | 4.51% | 5.32% | 2.52% | 0.58% | (11.87%) |
Return on Tangible Assets |
12.55% | 8.72% | 7.48% | 5.81% | 11.92% | 15.02% | 15.67% | 6.21% | (1.23%) | (44.99%) |
Average Days of Receivables |
54.52 | 77.35 | 65.87 | 66.21 | 60.01 | 54.86 | 61.74 | 61.40 | 61.73 | 62.24 |
Research and Development Expense of Revenue |
5.86% | 5.34% | 5.30% | 5.24% | 5.64% | 6.03% | 6.50% | 6.76% | 7.16% | 6.05% |
Selling, General and Administrative Expense of Revenue |
45.93% | 52.52% | 46.91% | 45.31% | 43.34% | 41.33% | 39.57% | 42.60% | 44.52% | 42.79% |
Intangible Assets out of Total Assets |
0.59 | 0.65 | 0.65 | 0.60 | 0.53 | 0.57 | 0.56 | 0.56 | 0.57 | 0.49 |
Share Based Compensation of Revenue |
1.74% | 1.81% | 1.41% | 1.40% | 1.43% | 2.35% | 1.78% | 1.31% | 1.51% | 1.14% |
Graham Net Nets |
(0.15) | (0.40) | (0.26) | (0.21) | (0.16) | (0.17) | (0.20) | (0.33) | (0.81) | (1.47) |
Graham Number |
15.24 | 15.20 | 16.40 | 14.69 | 25.19 | 29.77 | 32.51 | 19.24 | 0.00 | 0.00 |
Earnings Yield |
2.15% | 1.75% | 1.60% | 1.00% | 2.43% | 2.96% | 3.88% | 1.92% | (0.40%) | (54.19%) |
Free Cash Flow Yield |
2.19% | 1.98% | 3.27% | 3.24% | 3.07% | 4.66% | 5.05% | 2.11% | 1.43% | (3.26%) |
Revenue per Share |
13.34 | 15.45 | 17.77 | 17.72 | 16.21 | 18.21 | 18.77 | 19.25 | 20.91 | 21.33 |
Operating CF per Share |
1.56 | 1.49 | 2.41 | 2.70 | 2.41 | 3.69 | 3.19 | 1.75 | 1.68 | 0.66 |
Capex per Share |
(0.63) | (0.56) | (0.93) | (0.81) | (0.42) | (0.57) | (0.38) | (0.83) | (1.49) | (1.25) |
Free Cash Flow per Share |
0.93 | 0.93 | 1.48 | 1.89 | 1.99 | 3.12 | 2.81 | 0.91 | 0.19 | (0.59) |
Cash per Share |
1.37 | 2.27 | 1.68 | 2.32 | 5.55 | 6.06 | 5.50 | 3.86 | 3.55 | 3.44 |
Shareholders Equity per Share |
11.29 | 12.51 | 16.60 | 16.54 | 17.90 | 19.89 | 21.74 | 19.83 | 20.07 | 13.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.29 | 12.51 | 16.60 | 16.54 | 17.90 | 19.89 | 21.74 | 19.83 | 20.07 | 13.61 |
Free Cash Flow |
69.39 | 71.33 | 122.36 | 161.93 | 168.60 | 264.41 | 233.27 | 73.09 | 15.01 | (45.25) |
Working Capital |
371.57 | 473.24 | 512.53 | 526.86 | 836.19 | 813.70 | 840.59 | 751.06 | 159.56 | 703.56 |
Capital Expenditures |
(47.01) | (43.21) | (77.32) | (69.50) | (35.23) | (48.02) | (31.20) | (66.86) | (114.37) | (95.64) |
Net Current Asset Value |
(473.12) | (1,426.80) | (957.01) | (1,028.34) | (863.07) | (943.86) | (923.86) | (1,136.07) | (1,410.46) | (1,398.99) |
EV/EBIT |
32.37 | 116.57 | 44.45 | 65.62 | 43.25 | 34.08 | 23.54 | 42.28 | 114.12 | 0.00 |
Capex to Sales |
0.05 | 0.04 | 0.05 | 0.05 | 0.03 | 0.03 | 0.02 | 0.04 | 0.07 | 0.06 |
Price to Operating Income |
27.47 | 80.44 | 33.67 | 53.23 | 36.30 | 28.77 | 19.35 | 31.06 | 61.48 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.34 | 0.39 | 0.34 | 0.50 | 0.41 | 0.40 | 0.38 | 0.36 | 0.35 |
Cash ROIC |
4.32% | 2.40% | 4.26% | 5.44% | 4.81% | 7.03% | 6.27% | 2.16% | 0.42% | (1.45%) |
Accounts Receivable Turnover |
7.08 | 5.94 | 5.69 | 5.61 | 5.48 | 6.75 | 6.29 | 5.90 | 6.06 | 5.93 |
Accounts Payable Turnover |
10.94 | 7.08 | 6.72 | 5.97 | 6.21 | 10.27 | 7.17 | 6.76 | 8.33 | 9.02 |
Inventory Turnover |
1.63 | 1.70 | 1.98 | 1.89 | 1.66 | 1.91 | 1.83 | 1.84 | 1.78 | 1.74 |
Average Days of Payables |
30.38 | 78.75 | 48.57 | 73.10 | 38.27 | 37.76 | 63.45 | 51.30 | 41.34 | 43.48 |
Days of Inventory on Hand |
227.17 | 248.35 | 179.05 | 204.29 | 217.33 | 193.78 | 201.71 | 216.50 | 215.00 | 223.80 |
Average Receivables |
140.21 | 199.99 | 258.77 | 270.52 | 250.41 | 228.68 | 247.65 | 261.40 | 265.85 | 275.61 |
Average Payables |
31.91 | 61.51 | 85.01 | 94.57 | 83.85 | 58.22 | 81.97 | 97.21 | 87.41 | 89.11 |
Average Inventory |
214.35 | 256.80 | 288.34 | 298.20 | 313.09 | 313.75 | 320.98 | 357.10 | 409.35 | 460.91 |
Average Assets |
1,791.09 | 2,509.61 | 3,159.57 | 3,205.56 | 3,459.19 | 3,698.76 | 3,836.07 | 3,835.87 | 3,909.71 | 3,819.71 |
Average Common Equity |
795.55 | 900.99 | 1,169.05 | 1,396.27 | 1,465.80 | 1,599.84 | 1,744.60 | 1,696.14 | 1,566.58 | 1,294.37 |
Columns are period end dates